ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
1/1
0/0

5-Benzylidene-4-Oxazolidinones are Synergistic with Antibiotics for the Treatment of Staphylococcus Aureus Biofilms

preprint
submitted on 02.09.2019 and posted on 05.09.2019 by Bram Frohock, Jessica M. Gilbertie, Jennifer C. Daiker, Lauren V. Schnabel, Joshua Pierce
The failure of frontline antibiotics in the clinic is one of the most serious threats to human health and requires a multitude of novel therapeutics and innovative treatment approaches to curtail the growing crisis. In addition to traditional resistance mechanisms resulting in the lack of efficacy of many antibiotics, most chronic and recurring infections are further made tolerant to antibiotic action by the presence of biofilms. Herein, we report an expanded set of 5-benzylidene-4-oxazolidinones that are able to inhibit the formation of Staphylococcus aureus biofilms, disperse preformed biofilms and in combination with common antibiotics are able to significantly reduce the bacterial load in a robust collagen-matrix model of biofilm infection.

Funding

NIGMS, 1R01GM110154

History

Email Address of Submitting Author

jgpierce@ncsu.edu

Institution

NC State University

Country

USA

ORCID For Submitting Author

0000-0001-9194-3765

Declaration of Conflict of Interest

The authors declare the following competing financial interest(s): J.G.P. is a founder of Synoxa Sciences, Inc., a biotechnology company developing 4-oxazolidinones as antimicro-bial agents and anti-biofilm agents.

Exports